Cadila Healthcare Q4 Review - Margin Supported By Lower Research And Development: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Cadila Healthcare Ltd. reported Q4 FY21 performance largely in line with our estimates.
However, U.S. sales were weak while Ebitda margin was supported by reduced expenditure towards research and development.
Total revenue grew 3.2% to Rs 38.5 billion (our estimate: Rs 37.8 billion) supported by India formulations and consumer businesses.
Ebitda margin (ex-forex) improved 170 basis points to 22.2% (our estimate: 22.0%) driven by lower R&D spend (down 19.0% YoY).
The company has strengthened the balance sheet by substantial net debt reduction to ~Rs 35 billion, aided by internal accruals and equity raise of Rs 10 billion in Zydus Wellness Ltd. (subsidiary).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.